Volume 3 Supplement 1
Preliminary results of the initial human clinical trial of focused ultrasound to reposition kidney stones
© Bailey et al; licensee BioMed Central Ltd. 2015
Published: 30 June 2015
Ultrasonic propulsion is a new technology we have developed which uses focused ultrasound to transcutaneously reposition kidney stones. Two applications are expelling small stones or fragments and dislodging obstructing stones. We report preliminary, investigative findings from the first use of this technology in humans.
Ultrasonic Propulsion of Kidney Stones - Preliminary Results. All subjects treated with a combination of 50 V and 90V output
Number of Stones
Stone size (mm)
Total Push Bursts
Results and conclusions
Eight subjects have been enrolled and undergone ultrasonic propulsion to date. None of the subjects reported pain associated with the treatment. Subjects did report a mild warming of the skin with high (90 V) power pushes; no sensation was reported with low (50 V) power pushes. A summary of push movement results is provided in Table 1. Stones were visualized and repositioned in all subjects. One subject in the post-lithotripsy arm passed two small stones immediately following treatment. At least three post-lithotripsy subjects reported passage of multiple small fragments within two weeks of treatment. In five subjects, ultrasonic propulsion identified a collection of stones previously characterized as a single stone on KUB and ultrasound. Pre-operatively, one of two 7 mm stones was move before surgery. In surgery, it appeared one stone was firmly attached to Randall’s plaque and the other stone had been detached from Randall’s plaque and a 4 mm piece moved into the ureter. There have been no treatment related adverse events reported with mean follow-up of 3 months.
This is the first report of the successful repositioning of kidney stones in humans using ultrasound. Treatment was therapeutic in four subjects and provided diagnostic information in five. Subjects who did not have significant movement were the first patients and in the de novo arm. To date, there have been no reports of pain or adverse events associated with this treatment.
Trial supported by NSBRI through NASA NCC 9-58. Research and development supported by NIH DK043881and DK092197.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.